Targeting kidney mesangium by nanoparticles of defined size

Nanoparticles are being investigated for numerous medical applications and are showing potential as an emerging class of carriers for drug delivery. Investigations on how the physicochemical properties (e.g., size, surface charge, shape, and density of targeting ligands) of nanoparticles enable their ability to overcome biological barriers and reach designated cellular destinations in sufficient amounts to elicit biological efficacy are of interest. Despite proven success in nanoparticle accumulation at cellular locations and occurrence of downstream therapeutic effects (e.g., target gene inhibition) in a selected few organs such as tumor and liver, reports on effective delivery of engineered nanoparticles to other organs still remain scarce. Here, we show that nanoparticles of ~75 ± 25-nm diameters target the mesangium of the kidney. These data show the effects of particle diameter on targeting the mesangium of the kidney. Because many diseases originate from this area of the kidney, our findings establish design criteria for constructing nanoparticle-based therapeutics for targeting diseases that involve the mesangium of the kidney.

[1]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[2]  G. Schreiner The mesangial phagocyte and its regulation of contractile cell biology. , 1992, Journal of the American Society of Nephrology : JASN.

[3]  Feng Zhao,et al.  Acute toxicological effects of copper nanoparticles in vivo. , 2006, Toxicology letters.

[4]  A. Evan,et al.  Effects of moxalactam and cefotaxime on rabbit renal tissue , 1982, Antimicrobial Agents and Chemotherapy.

[5]  H. Makino,et al.  High-Resolution Ultrastructural Comparison of Renal Glomerular and Tubular Basement Membranes , 1999, American Journal of Nephrology.

[6]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[7]  Hak Soo Choi,et al.  Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. , 2009, Nano letters.

[8]  Vincent Castranova,et al.  Nanoparticle inhalation augments particle-dependent systemic microvascular dysfunction , 2008, Particle and Fibre Toxicology.

[9]  D. Parker,et al.  An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. , 2010, Molecular pharmaceutics.

[10]  Patrick Brochard,et al.  In vitro effects of nanoparticles on renal cells , 2008, Particle and Fibre Toxicology.

[11]  K. Lounatmaa,et al.  Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  Robert Sinclair,et al.  Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. , 2008, Small.

[13]  Matthew Tirrell,et al.  Polymers tethered to curves interfaces: a self-consistent-field analysis , 1992 .

[14]  Håkan Wallin,et al.  Kupffer cells are central in the removal of nanoparticles from the organism , 2007, Particle and Fibre Toxicology.

[15]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[16]  N. Dhalla,et al.  Excitation-contraction coupling in heart. 3. Evidence against the involvement of adenosine cyclic 3',5'-monophosphate in calcium transport by sarcotubular vesicles of canine myocardium. , 1970, Molecular pharmacology.

[17]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[18]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[19]  Alexandra Schneider,et al.  Ultrafine particles and platelet activation in patients with coronary heart disease – results from a prospective panel study , 2007, Particle and Fibre Toxicology.

[20]  M. Farquhar,et al.  Presence of heparan sulfate in the glomerular basement membrane. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.